Pfizer and Valneva announced that their Lyme disease vaccine candidate PF-07307405 (LB6V) demonstrated over 70% efficacy in preventing Lyme disease in people aged five years and older during Phase 3 VALOR trial. The companies also announced Valneva's participation in the 26th World Vaccine Congress in Washington DC.
Pfizer Inc. (PFE)
Common Stock · Currency in USD · XNYS
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
Company Info
SIC2834
Composite FIGIBBG000BR2B91
CIK0000078003
IPOJun 22, 1951
Sectorpharmaceutical preparations
Highlights
Market Cap$161.09B
EPS$2.48
P/E Ratio11.34
Revenue$62.61B
Gross Profit$49.93B
Net Income$14.20B
Employees75,000
WSO5,688,356,129
Phone(212) 733-2323
Websitehttps://www.pfizer.com
Related Tickers
MRNA
Moderna, Inc. Common Stock
$49.38 0.00%
MRK
Merck & Co., Inc.
$120.87 0.00%
JNJ
Johnson & Johnson
$242.50 0.00%
NVAX
Novavax Inc
$7.75 0.00%
LLY
Eli Lilly & Co.
$935.98 0.00%
ABBV
ABBVIE INC.
$208.27 0.00%
AZN
AstraZeneca PLC
$204.93 0.00%
BMY
Bristol-Myers Squibb Co.
$59.56 0.00%
AMGN
Amgen Inc
$347.78 0.00%
GILD
Gilead Sciences Inc
$139.89 0.00%
Analysis
Share Price Chart
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Pfizer Inc., comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Returns By Period
Pfizer Inc. (PFE) has returned 13.37% so far this year and 27.91% over the past 12 months. Looking at the last ten years, PFE has achieved an annualized return of -0.60%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
PFE
1M7.31%
6M3.85%
YTD13.37%
1Y27.91%
5Y-4.94%
10Y-0.60%
Benchmark (SPY)
1M-3.85%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of Pfizer Inc. (PFE) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 5.84% | 4.66% | 1.85% | 0.18% | ||||||||
| 2025 | -0.86% | 0.49% | -3.91% | -3.48% | -3.33% | 2.97% | -4.06% | 6.27% | 3.03% | -5.08% | 4.68% | -3.34% |
| 2024 | -6.23% | -1.99% | 3.45% | -7.71% | 8.85% | -2.37% | 9.27% | -5.57% | 1.01% | -2.58% | -7.97% | 1.76% |
| 2023 | -13.43% | -7.60% | 0.59% | -4.42% | -2.51% | -3.78% | -1.21% | -1.39% | -6.93% | -7.25% | -0.29% | -0.62% |
| 2022 | -9.93% | -11.00% | 10.88% | -5.85% | 11.24% | -1.54% | -2.94% | -10.12% | -3.06% | 5.63% | 4.44% | 1.85% |
| 2021 | -2.63% | -6.79% | 7.86% | 6.47% | -0.79% | 0.56% | 9.29% | 6.40% | -6.88% | 2.87% | 21.73% | 12.54% |
| 2020 | -5.24% | -10.78% | -3.75% | 20.18% | 0.90% | -7.89% | 11.41% | -2.12% | -2.88% | -3.87% | 6.62% | -6.57% |
| 2019 | -1.55% | 1.12% | -2.61% | -4.63% | 2.29% | 4.06% | -10.73% | -7.20% | 0.90% | 6.79% | -0.44% | 1.01% |
| 2018 | 1.81% | -0.82% | -1.74% | 3.36% | 0.98% | 0.06% | 10.92% | 4.77% | 6.24% | -2.20% | 7.01% | -5.87% |
| 2017 | -2.97% | 8.28% | -0.18% | -0.56% | -3.66% | 2.82% | -0.96% | 2.66% | 5.19% | -1.71% | 3.57% | -0.19% |
| 2016 | 11.11% | 6.57% | 1.62% | 4.95% | -6.00% | -2.48% | -5.99% | 3.88% | 0.71% |
Performance Indicators
The charts below present risk-adjusted performance metrics for Pfizer Inc. (PFE) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of PFE compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current Pfizer Inc. volatility is 1.37%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 208.16B | 213.40B | 226.50B | 197.21B | 181.48B | 154.23B | 167.49B | 159.42B | 171.80B | 171.62B | 167.46B | 169.27B | 172.10B | 185.80B | 188.00B | 195.01B |
| Equity Attributable To Parent (USD) | 86.48B | 88.20B | 89.01B | 95.66B | 77.20B | 63.24B | 63.14B | 63.41B | 71.31B | 59.54B | 64.72B | 71.30B | 76.31B | 81.26B | 82.19B | 87.81B |
| Equity Attributable To Noncontrolling Interest (USD) | 299.00M | 294.00M | 274.00M | 256.00M | 262.00M | 235.00M | 303.00M | 351.00M | 348.00M | 296.00M | 278.00M | 321.00M | 313.00M | 418.00M | 431.00M | 452.00M |
| Equity (USD) | 86.78B | 88.50B | 89.29B | 95.92B | 77.46B | 63.47B | 63.45B | 63.76B | 71.66B | 59.84B | 65.00B | 71.62B | 76.62B | 81.68B | 82.62B | 88.27B |
| Other Non-current Liabilities (USD) | - | - | - | - | - | 60.84B | - | - | - | 49.26B | 44.25B | 44.48B | - | - | - | - |
| Long-term Debt (USD) | - | - | - | - | - | 4.00B | - | - | - | 31.40B | 28.82B | 31.54B | - | - | - | - |
| Noncurrent Liabilities (USD) | 84.40B | 81.90B | 89.42B | 59.15B | 61.34B | 64.84B | 66.74B | 63.81B | 69.71B | 80.66B | 73.06B | 76.02B | 72.12B | 75.50B | 77.31B | 78.14B |
| Other Current Liabilities (USD) | 28.13B | 33.52B | 38.31B | 31.92B | 33.76B | 18.55B | 30.36B | 24.79B | 23.58B | 24.09B | 23.42B | 16.41B | 18.34B | 22.31B | 22.06B | 22.48B |
| Wages (USD) | 3.61B | 3.84B | 2.78B | 3.41B | 3.33B | 3.06B | 2.72B | 2.40B | 2.20B | 2.49B | 2.36B | 1.78B | 1.79B | 2.05B | 2.17B | 2.11B |
| Accounts Payable (USD) | 5.24B | 5.63B | 6.71B | 6.81B | 5.58B | 4.31B | 4.22B | 4.67B | 4.66B | 4.54B | 3.62B | 3.44B | 3.23B | 4.26B | 3.84B | 4.03B |
| Current Liabilities (USD) | 36.98B | 43.00B | 47.79B | 42.14B | 42.67B | 25.92B | 37.30B | 31.86B | 30.43B | 31.12B | 29.40B | 21.63B | 23.37B | 28.62B | 28.07B | 28.61B |
| Liabilities (USD) | 121.39B | 124.90B | 137.21B | 101.29B | 104.01B | 90.76B | 104.04B | 95.66B | 100.14B | 111.78B | 102.46B | 97.65B | 95.48B | 104.12B | 105.38B | 106.75B |
| Other Non-current Assets (USD) | 92.21B | 89.23B | 99.33B | 86.30B | 81.76B | 76.79B | 85.35B | 60.48B | 68.25B | 66.70B | 69.53B | 64.64B | 64.08B | 63.91B | 50.05B | 48.12B |
| Intangible Assets (USD) | 53.73B | 55.41B | 64.90B | 43.37B | 25.15B | 28.47B | 35.37B | 35.21B | 48.74B | 52.65B | 40.36B | 35.17B | 39.39B | 46.01B | 53.83B | 57.56B |
| Fixed Assets (USD) | 19.32B | 18.39B | 18.94B | 16.27B | 14.88B | 13.90B | 13.97B | 13.39B | 13.87B | 13.32B | 13.77B | 11.76B | 12.40B | 14.46B | 16.94B | 19.12B |
| Long Term Investments (USD) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.46B | 9.75B |
| Noncurrent Assets (USD) | 165.26B | 163.04B | 183.17B | 145.95B | 121.78B | 119.16B | 134.69B | 109.07B | 130.86B | 132.67B | 123.66B | 111.57B | 115.86B | 124.38B | 130.27B | 134.55B |
| Other Current Assets (USD) | 32.24B | 39.51B | 33.14B | 42.28B | 50.63B | 27.02B | 24.52B | 42.42B | 33.56B | 32.17B | 36.29B | 52.04B | 50.08B | 54.35B | 49.96B | 52.06B |
| Inventory (USD) | 10.65B | 10.85B | 10.19B | 8.98B | 9.06B | 8.05B | 8.28B | 7.51B | 7.58B | 6.78B | 7.51B | 5.66B | 6.17B | 7.06B | 7.77B | 8.41B |
| Current Assets (USD) | 42.90B | 50.36B | 43.33B | 51.26B | 59.69B | 35.07B | 32.80B | 49.93B | 41.14B | 38.95B | 43.80B | 57.70B | 56.24B | 61.42B | 57.73B | 60.47B |
| Assets (USD) | 208.16B | 213.40B | 226.50B | 197.21B | 181.48B | 154.23B | 167.49B | 159.00B | 172.00B | 171.62B | 167.46B | 169.27B | 172.10B | 185.80B | 188.00B | 195.01B |
News and Insights
Pfizer and Valneva announced that their Lyme disease vaccine candidate PF-07307405 (LB6V) demonstrated over 70% efficacy in preventing Lyme disease in individuals aged five years and older in Phase 3 VALOR trial. The vaccine candidate was well-tolerated.
The article recommends three dividend stocks for long-term investors: Philip Morris International, which is expanding into smoke-free nicotine products with strong growth; Pfizer, offering a high 6.2% dividend yield despite being down 55% from highs and facing headwinds in obesity drugs; and UnitedHealth Group, a health insurer down 58% from highs but expected to rebound with strong earnings growth driven by an aging U.S. population.
The Trump administration is preparing to announce 100% tariffs on pharmaceutical companies that haven't secured pricing deals with the White House, potentially as soon as Thursday. The tariffs stem from a Section 232 investigation citing national security grounds. Major drugmakers including Pfizer, Eli Lilly, AstraZeneca, Novo Nordisk, and Johnson & Johnson have already secured three-year reprieves by agreeing to most-favored-nation pricing. The tariff threat is part of a broader pricing strategy that includes the TrumpRx.gov platform for comparing discounted drug prices.
The global esophageal cancer market is projected to grow at a CAGR of 9.5% from $1.65 billion in 2026 to $2.37 billion by 2030, driven by advancements in precision oncology, immunotherapies, and minimally invasive procedures. Major pharmaceutical companies including Pfizer, Roche, and Merck are leading the market through product innovation and personalized cancer care solutions.
Despite setbacks including a failed GLP-1 drug candidate and a 50% stock decline from 2021 highs, Pfizer demonstrates resilience by quickly acquiring a promising GLP-1 competitor and showing progress in early 2026. The article argues that long-term investors shouldn't count out the pharmaceutical giant, which maintains a $150B market cap, a 6.2% dividend yield, and a track record of navigating industry challenges.
Viking Therapeutics' VK2735, a GLP-1 weight loss drug candidate, could become a major player in the $100 billion weight loss market. Upcoming phase 3 clinical trial results could trigger a threefold stock surge if positive, making Viking an acquisition target. However, the investment is highly binary and risky, with significant downside if trials disappoint.
While Eli Lilly dominates the GLP-1 drug market with impressive sales growth from Mounjaro and Zepbound, the stock trades at a lofty 40x P/E ratio—well above pharma averages. The article warns that investors have priced in perfection, ignoring inevitable patent expirations and increasing competition from rivals developing alternative GLP-1 formulations. Despite strong current performance, the valuation makes Eli Lilly an unattractive long-term investment at current prices.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALNnegative
Pomerantz LLP is investigating potential securities fraud claims against Valneva SE and partner Pfizer following the failure of their Phase 3 Lyme disease vaccine candidate (LB6V) to meet its primary endpoint. The announcement triggered a sharp 37.11% decline in Valneva's ADR price on March 23, 2026.
Serina Therapeutics, a clinical-stage biotech company, announced that CEO Steve Ledger will present at the 38th Annual Roth Conference on March 24, 2026. The company is developing its proprietary POZ Platform™ technology for drug optimization, with a focus on treating neurological diseases. Serina has a pipeline including SER-252 (POZ-apomorphine) for Parkinson's disease and has secured partnerships including a non-exclusive license agreement with Pfizer for lipid nanoparticle drug delivery applications.